Abstract: A semiconductor device is described. The semiconductor device includes: a semiconductor substrate having an edge, an active area spaced inward from the edge, and an edge termination area laterally surrounding the active area; and a plurality of transistor cells formed in the active area, each transistor cell including a source region of a first conductivity type and a body region of a second conductivity type opposite the first conductivity type. The edge termination area includes a plurality of needle-shaped compensation trenches and is devoid of complete transistor cells. A body doping region of the second conductivity type and that includes the body regions of the transistor cells extends from the active area into the edge termination area. The body doping region in the edge termination area is physically and electrically isolated from the body doping region in the active area.

Abstract: According to an embodiment, a transistor device includes a semiconductor body. The semiconductor body has a first surface, a second surface opposing the first surface, side faces, an active area, an edge termination region that laterally surrounds the active area, a drain region of a first conductivity type at the second surface, a drift region of the first conductivity type on the drain region, and a body region of a second conductivity type that opposes the first conductivity type on the drift region. In the active area, a source region of the first conductivity type is arranged on the body region. The body region has a doping concentration that is higher in the active area than in the edge termination region.

Abstract: A method for channel management in an optical network unit includes receiving a disable channel action message sent by an optical line terminal, wherein the disable channel action message is used to instruct disabling a first channel of the optical network unit; transferring the state machine of the optical network unit on the first channel from the association substate of the operation state to the pending substate according to the disable channel action message; and turning off the transmitter and/or the receiver on the first channel after a specified time is reached, transferring the state machine from the pending substate of the operation state to the disabling channel status, and starting a timer.

Abstract: A method for channel management in an optical network unit includes receiving a disable channel action message sent by an optical line terminal, wherein the disable channel action message is used to instruct disabling a first channel of the optical network unit; transferring the state machine of the optical network unit on the first channel from the association substate of the operation state to the pending substate according to the disable channel action message; and turning off the transmitter and/or the receiver on the first channel after a specified time is reached, transferring the state machine from the pending substate of the operation state to the disabling channel status, and starting a timer.

Abstract: The present invention relates to a preparation method for a chiral intermediate for use in statins, acquired with chloroacetic acid and benzyl alcohol as starting materials via a series of reactions, namely etherification, condensation, substitution, and asymmetric reduction. The preparation method provided in the present invention has a novel route of synthesis, allows an intermediate compound to be introduced conveniently into the chiral center of a glycol via enzyme reduction, and not only is low in costs, but also is reliable in quality. The route of synthesis provided in the present invention uses raw materials of low costs, has an easy to operate process, and provides a final product of great purity and high yield.

Abstract: The application provides a Diketoreductase (DKR) mutant, its nucleotide coding sequence, and an expression cassette, recombinant vector and host cell containing the sequence, as well as a method for application of the mutant to the preparation of 3R,5S-dicarbonyl compound. An ee value of the obtained 3R,5S-dicarbonyl compound is higher than 99%, and a de value is about 90%. The DKR mutant is a key pharmaceutical intermediate, and particularly provides an efficient catalyst for synthesis of a chiral dicarbonyl hexanoic acid chain of a statin drug.

Abstract: The present invention relates to a preparation method for a chiral intermediate for use in statins, acquired with chloroacetic acid and benzyl alcohol as starting materials via a series of reactions, namely etherification, condensation, substitution, and asymmetric reduction. The preparation method provided in the present invention has a novel route of synthesis, allows an intermediate compound to be introduced conveniently into the chiral center of a glycol via enzyme reduction, and not only is low in costs, but also is reliable in quality. The route of synthesis provided in the present invention uses raw materials of low costs, has an easy to operate process, and provides a final product of great purity and high yield.

Abstract: The application provides a Diketoreductase (DKR) mutant, its nucleotide coding sequence, and an expression cassette, recombinant vector and host cell containing the sequence, as well as a method for application of the mutant to the preparation of 3R,5S-dicarbonyl compound. An ee value of the obtained 3R,5S-dicarbonyl compound is higher than 99%, and a de value is about 90%. The DKR mutant is a key pharmaceutical intermediate, and particularly provides an efficient catalyst for synthesis of a chiral dicarbonyl hexanoic acid chain of a statin drug.

Abstract: A synthesis method for L-cyclic alkyl amino acid and a pharmaceutical composition having the said amino acid are provide in the present disclosure provides. The synthesis method comprises: step A.) preparing a cyclic alkyl keto acid or a cyclic alkyl keto acid salt having Structural Formula (I) or Structural Formula (II), and step B.) mixing the cyclic alkyl keto acid or the cyclic alkyl keto acid salt with ammonium formate, a leucine dehydrogenase, a formate dehydrogenase and a coenzyme NAD+, and carrying out a reductive amination reaction to generate the L-cyclic alkyl amino acid, wherein the Structural Formula (I) is where n1?1, m1?0 and the M1 is H or a monovalent cation; the Structural Formula (II) is where n2?0, m2?0, the M2 is H or a monovalent cation, an amino acid sequence of the leucine dehydrogenase is SEQ ID No.1.

Abstract: A synthesis method for an L-heterocyclic amino acid and a pharmaceutical composition having the said amino acid are provided in the present disclosure. The synthesis method comprises: step A: preparing a heterocyclic keto acid, wherein the heterocycle in the heterocyclic keto acid is selected from any one of a five-membered heterocycle, a six-membered heterocycle, a seven-membered heterocycle, an alkyl-substituted five-membered heterocycle, an alkyl-substituted six-membered heterocycle, and an alkyl-substituted seven-membered heterocycle, and the keto acid group in the heterocyclic keto acid has a structural formula of and is located on any one of the carbon positions of the heterocycle, and step B: mixing the heterocyclic keto acid with ammonium formate, a phenylalanine dehydrogenase, a formate dehydrogenase and a coenzyme NAD+, and carrying out a reductive amination reaction to generate L-heterocyclic amino acid, wherein the amino acid sequence of the phenylalanine dehydrogenase is SEQ ID No. 1.